Condition: Metastatic Castration-Resistant Prostate Cancer (mCRPC) · Clear Cell Renal Cell Carcinoma (ccRCC) · Sponsor: Regeneron Pharmaceuticals
The main purpose of this study is to determine the safety, tolerability (how the body reacts to the drug\[s\]) and effectiveness (ability to treat the cancer) of REGN5678 (Nezastomig) alone, or in combination with cemiplimab. The study has 2 parts. The goal of Part 1 (dose escalation) is to determine a safe dose(s) of REGN5678 when it is given alone or in combination with cemiplimab. The goal of Part 2 (dose expansion) is to use the REGN5678 drug dose(s) found in Part 1 to see how well REGN5678 alone or in combination with cemiplimab works to shrink tumors. This study is looking at several other research questions, including: 1. Side effects that may be experienced by taking REGN5678 alone or in combination with cemiplimab 2. How REGN5678 alone or in combination with cemiplimab works in the body 3. How much REGN5678 and/or cemiplimab are present in the blood 4. To see if REGN5678 alone or in combination with cemiplimab works to reduce the size of the tumor by helping the immune system destroy the tumor
This description comes directly from the study's public registry record.
Clinical Trials Administrator · 844-734-6643 · clinicaltrials@regeneron.com
Always discuss trial participation with your own doctor first.
| Banner MD Anderson Cancer Center | Gilbert, Arizona, United States | Recruiting |
| Mayo Clinic | Phoenix, Arizona, United States | Recruiting |
| University of Arizona | Tucson, Arizona, United States | Recruiting |
| John Wayne Cancer Institute (JWCI) | Santa Monica, California, United States | Recruiting |
| Sarah Cannon Research Institute (SCRI) | Denver, Colorado, United States | Recruiting |
| Yale University Hospital | New Haven, Connecticut, United States | Recruiting |
| Mayo Clinic Jacksonville | Jacksonville, Florida, United States | Recruiting |
| Moffitt Cancer Center - McKinley Drive | Tampa, Florida, United States | Recruiting |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
| Henry Ford Health | Detroit, Michigan, United States | Recruiting |
| Mayo Clinic | Rochester, Minnesota, United States | Recruiting |
| NYU Langone Health Perlmutter Cancer Center | New York, New York, United States | Recruiting |
+ 12 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03972657